Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2018 Dec 20

PMID 30564155

Citations 85

Authors

Hannah Zuckerman

Zihang Pan

Caroline Park

Elisa Brietzke

Natalie Musial

Aisha S Shariq

Michelle Iacobucci

Samantha J Yim

Leanna M W Lui

Carola Rong

Roger S McIntyre

Affiliations

Soon will be listed here.

Abstract

Major Depressive Disorder (MDD) is a prevalent, chronic, disabling, and multidimensional mental disorder. Cognitive dysfunction represents a core diagnostic and symptomatic criterion of MDD, and is a principal determinant of functional non-recovery. Cognitive impairment has been observed to persist despite remission of mood symptoms, suggesting dissociability of mood and cognitive symptoms in MDD. Recurrent impairments in several domains including, but not limited to, executive function, learning and memory, processing speed, and attention and concentration, are associated with poor psychosocial and occupational outcomes. Attempts to restore premorbid functioning in individuals with MDD requires regular screenings and assessment of objective and subjective measures of cognition by clinicians. Easily accessible and cost-effective tools such as the THINC-integrated tool (THINC-it) are suitable for use in a busy clinical environment and appear to be promising for routine usage in clinical settings. However, antidepressant treatments targeting specific cognitive domains in MDD have been insufficiently studied. While select antidepressants, e.g., vortioxetine, have been demonstrated to have direct and independent pro-cognitive effects in adults with MDD, research on additional agents remains nascent. A comprehensive clinical approach to cognitive impairments in MDD is required. The current narrative review aims to delineate the importance and relevance of cognitive dysfunction as a symptomatic target for prevention and treatment in the phenomenology of MDD.

Citing Articles

Association between overt aggression and suicidal ideation in patients with major depressive disorder: the mediational role of cognitive symptoms.

Chen N, Wang M, Chen Y, Wang F, Huang Q, Lyu D Eur Arch Psychiatry Clin Neurosci. 2025; .

PMID: 40035832 DOI: 10.1007/s00406-025-01979-0.

Long Sleep Duration, Cognitive Performance, and the Moderating Role of Depression: A Cross-Sectional Analysis in the Framingham Heart Study.

Young V, Bernal R, Baril A, Zeynoun J, Wiedner C, Gaona C medRxiv. 2024; .

PMID: 39677456 PMC: 11643162. DOI: 10.1101/2024.12.02.24318350.

Cognitive Dysfunction in Unipolar Depression.

Rakesh C , Sharma R, Singh C Indian J Psychol Med. 2024; :02537176241259683.

PMID: 39564278 PMC: 11572421. DOI: 10.1177/02537176241259683.

TCEDN: A Lightweight Time-Context Enhanced Depression Detection Network.

Yan K, Miao S, Jin X, Mu Y, Zheng H, Tian Y Life (Basel). 2024; 14(10).

PMID: 39459613 PMC: 11509182. DOI: 10.3390/life14101313.

VGLUT2 may improve cognitive function in depressed rats by protecting prefrontal cortex neurons.

Liu L, Hu Y, Shan Q, Li P, Ma T, Wang Y Front Behav Neurosci. 2024; 18:1453161.

PMID: 39301432 PMC: 11410701. DOI: 10.3389/fnbeh.2024.1453161.

References

Krystal J, DSouza D, Karper L, Bennett A, Abi-Dargham A, Abi-Saab D . Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl). 1999; 145(2):193-204. DOI: 10.1007/s002130051049. View

Fossati P, Hevenor S, Graham S, Grady C, Keightley M, Craik F . In search of the emotional self: an fMRI study using positive and negative emotional words. Am J Psychiatry. 2003; 160(11):1938-45. DOI: 10.1176/appi.ajp.160.11.1938. View

Morgan C, Mofeez A, Brandner B, Bromley L, Curran H . Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology. 2003; 29(1):208-18. DOI: 10.1038/sj.npp.1300342. View

Kubesch S, Bretschneider V, Freudenmann R, Weidenhammer N, Lehmann M, Spitzer M . Aerobic endurance exercise improves executive functions in depressed patients. J Clin Psychiatry. 2003; 64(9):1005-12. DOI: 10.4088/jcp.v64n0905. View

Ressler K, Nemeroff C . Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr. 2004; 6(8):663-6, 670. DOI: 10.1017/s1092852900001358. View

Rowland L, Astur R, Jung R, Bustillo J, Lauriello J, Yeo R . Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology. 2005; 30(3):633-9. DOI: 10.1038/sj.npp.1300642. View

DeRubeis R, Hollon S, Amsterdam J, Shelton R, Young P, Salomon R . Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005; 62(4):409-16. DOI: 10.1001/archpsyc.62.4.409. View

Paelecke-Habermann Y, Pohl J, Leplow B . Attention and executive functions in remitted major depression patients. J Affect Disord. 2005; 89(1-3):125-35. DOI: 10.1016/j.jad.2005.09.006. View

Trivedi M, Rush A, Wisniewski S, Nierenberg A, Warden D, Ritz L . Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163(1):28-40. DOI: 10.1176/appi.ajp.163.1.28. View

10.

Zimmerman M, McGlinchey J, Posternak M, Friedman M, Boerescu D, Attiullah N . Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: implications for how remission from depression should be defined. Psychiatry Res. 2006; 141(2):185-91. DOI: 10.1016/j.psychres.2005.05.016. View

11.

Lemos-Miller A, Kearney C . Depression and ethnicity as intermediary variables among dissociation, trauma-related cognitions, and PTSD symptomatology in youths. J Nerv Ment Dis. 2006; 194(8):584-90. DOI: 10.1097/01.nmd.0000230407.12687.ba. View

12.

Jaeger J, Berns S, Uzelac S, Davis-Conway S . Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006; 145(1):39-48. DOI: 10.1016/j.psychres.2005.11.011. View

13.

Perry Jr E, Cramer J, Cho H, Petrakis I, Karper L, Genovese A . Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007; 192(2):253-60. DOI: 10.1007/s00213-007-0706-2. View

14.

Airaksinen E, Wahlin A, Forsell Y, Larsson M . Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up. Acta Psychiatr Scand. 2007; 115(6):458-65. DOI: 10.1111/j.1600-0447.2006.00932.x. View

15.

Raskin J, Wiltse C, Siegal A, Sheikh J, Xu J, Dinkel J . Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007; 164(6):900-9. DOI: 10.1176/ajp.2007.164.6.900. View

16.

Miskowiak K, Papadatou-Pastou M, Cowen P, Goodwin G, Norbury R, Harmer C . Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. Neuroimage. 2007; 37(3):904-11. DOI: 10.1016/j.neuroimage.2007.05.036. View

17.

Mathews A, Macleod C . Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2007; 1:167-95. DOI: 10.1146/annurev.clinpsy.1.102803.143916. View

18.

Herrmann L, le Masurier M, Ebmeier K . White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2007; 79(6):619-24. DOI: 10.1136/jnnp.2007.124651. View

19.

Reger M, Watson G, Green P, Wilkinson C, Baker L, Cholerton B . Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2007; 70(6):440-8. DOI: 10.1212/01.WNL.0000265401.62434.36. View

20.

Gorwood P, Corruble E, Falissard B, Goodwin G . Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry. 2008; 165(6):731-9. DOI: 10.1176/appi.ajp.2008.07040574. View